Maroun Aoun

Dr. Maroun Aoun


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in International Journal of Breast Cancer
Verified
Journal Article
Open access
GHGeorges El Haddad
Georges El Haddad
EDErnest Diab
Ernest Diab
MHMichel Hajjar
Michel Hajjar
MAMaroun Aoun
Maroun Aoun
FMFarid Mallat
Farid Mallat
HKHampig-Raphael Kourie
Hampig-Raphael Kourie
Human epidermal growth factor receptor 2 (HER2)‐low breast cancer (BC) is a subtype of BC that has been recently recognized as a separate clinical entity with distinct clinical and molecular characteristics. It is defined by a low level of HER2 protein expression, which distinguishes it from other more aggressive BC subtypes. Early studies suggest that it may have a more favorable prognosis than HER2‐positive BC, as it is less likely to spread to other parts of the body and may be more responsive to standard BC treatments such as chemotherapy, radiation therapy, and hormone therapy. Given the relative new emergence of HER2‐low BC, there is still much to be learned about this subtype; ongoing research is focused on identifying the underlying genetic mutations that contribute to HER2‐low BC as well as developing targeted therapies that can improve outcomes for patients with this disease. This review is aimed at summarizing the current clinical knowledge on HER2‐low BC, with the aim of creating a better understanding of this entity and paving the way for potential interventions and a new standard of care.

1 January 2024 in Clinics in Orthopedic Surgery
Verified
Journal Article
Open access
PDF file
MAMaroun Aoun
Maroun Aoun
RCRalph Chalhoub
Ralph Chalhoub
FNFong H Nham
Fong H Nham
EKEliana Kassis
Eliana Kassis
MDMohammad Daher
Mohammad Daher
MEMouhanad M El-Othmani
Mouhanad M El-Othmani
Aoun M, et al. Clin Orthop Surg. 2024 Dec;16(6):880-889. https://doi.org/10.4055/cios24114

1 March 2025 in Hip & Pelvis
Verified
Journal Article
Open access
PDF file
RCRalph Chalhoub
Ralph Chalhoub
MAMaroun Aoun
Maroun Aoun
FNFong H. Nham
Fong H. Nham
EKEliana Kassis
Eliana Kassis
MDMohammad Daher
Mohammad Daher
BSBs
Bs
Ralph Chalhoub, MD, Maroun Aoun, BS, Fong H. Nham, MD, Eliana Kassis, MD, Mohammad Daher, BS, Mouhanad M. El-Othmani, MD. Hip Pelvis 2025;37:53-63. https://doi.org/10.5371/hp.2025.37.1.53

26 September 2025 in Rheumatology
Verified
Journal Article
Closed access
MAMaroun Aoun
Maroun Aoun
SGSherif M Gamal
Sherif M Gamal
IHIhsane Hmamouchi
Ihsane Hmamouchi
Clementina López-MedinaClementina López-Medina
Clementina López-Medina
MDMaxime Dougados
Maxime Dougados
NZNelly Raymond Ziadé
Nelly Raymond Ziadé
Objectives: Diagnostic delay (DD) is well-documented in SpA, particularly in axial disease. This ancillary analysis from the ASAS-PerSpA study estimated DD across SpA entities, considering the presenting disease manifestation, and evaluated factors associated with DD. Methods: This study included 4339 patients with any SpA entity (axial (axSpA), peripheral (pSpA), PsA, inflammatory bowel disease-associated SpA (IBD-SpA), ReA and juvenile SpA). DD was assessed using two definitions: (1) the first included extra-musculoskeletal manifestation (EMM) if any, as possible initial symptom, and (2) the second considered strictly the first musculoskeletal manifestation (MM) as the disease onset. DD was statistically compared across disease entities, and associated factors were evaluated using multivariable linear regression models for axSpA, PsA, pSpA and IBD-SpA. Results: The analysis included 2622 axSpA, 1016 PsA, 424 pSpA, 110 IBD-SpA, and 167 other SpA patients. The average DD was shorter using definition 2 (4.5 ± 7.0 vs 6.6 ± 8.6 years). Based on definition 2, DD was longer for axSpA and IBD-SpA (5.6 ± 7.3 and 5.2 ± 7.7 years, respectively), where the first MM was axial, compared with PsA (2.5 ± 6.1 years), pSpA (3.1 ± 5.9 years) and others, where it was peripheral (P < 0.001). Axial first manifestation, younger age at first symptom and older age at study inclusion were associated with longer DD in the four SpA entities. Conclusion: DD was longer in axSpA and IBD-SpA compared with PsA, pSpA and other forms of SpA and associated with the phenotype of the presenting symptom. SpA entities and presenting symptoms should be considered when reporting DD in SpA.

1 March 2025 in Hip & Pelvis
Verified
Journal Article
Open access
PDF file
MBMarc Boutros
Marc Boutros
MDMd
Md
MAMaroun Aoun
Maroun Aoun
FNFong H. Nham
Fong H. Nham
EKEliana Kassis
Eliana Kassis
MEMouhanad M. El-Othmani
Mouhanad M. El-Othmani
Marc Boutros, MD, Maroun Aoun, MD, Fong H. Nham, MD, Eliana Kassis, MD, Mohammad Daher, MD, Mouhanad M. El-Othmani, MD. Hip Pelvis 2025;37:45-52. https://doi.org/10.5371/hp.2025.37.1.45

14 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MAMaroun Aoun
Maroun Aoun
FMFarid Mallat
Farid Mallat
RJRita Jabbour
Rita Jabbour
SHSamir Hachem
Samir Hachem
BSBoutros Soutou
Boutros Soutou
JHJosiane Helou
Josiane Helou
Objective: To assess the response to intramuscular vitamin D in patients not respond-ing to oral supplementation. Methods: A retrospective series included patients, with systemic sclerosis and a history of subclinical poor vitamin D status that was resistant to at least 6 months of oral supplementation, to whom intramuscular vitamin D2 was administered. Results: Twelve patients were identified, with a mean age of 47.8 years. All were women. Five had diffuse systemic sclerosis and seven had localized systemic sclerosis. The mean duration of the disease was 17.9 years, with a mean modified Rod-nan skin score of 14.9. All patients were twice injected, at a 15-day interval, 300,000 IU of ergocalciferol into the anterior gluteus muscle. The mean serum level of 25(OH)D increased from 12.9 ng/mL before the first injection, to 23 ng/mL two weeks after the first injection, and 37.1 ng/mL four weeks after the second injection (p<0.001). No side effects were observed. Conclusion: It is the first report of safely normalizing vitamin D levels with intramuscular ergocalciferol in patients with systemic sclerosis.